⌕
Tango Therapeutics · TNGX · Nasdaq
Tenet — · insufficient data
Compare
$22.11−8.52%At close
$22.11−2.06 (−8.52%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Tango Therapeutics (TNGX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is TNGX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 15, 2026 · 11:27 ETEARNINGS EXPECTED BY FEB 23
Tango Therapeutics, Inc. $TNGX Stock Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 84.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned …

TNGX −8.5% todayRead at source ↗
● Defense WorldNov 11, 2026 · 04:05 ETEARNINGS EXPECTED BY FEB 23
Tango Therapeutics (NASDAQ:TNGX) Stock Price Breaks Above 50-Day Moving Average After Earnings Miss

Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Tuesday after the company announced better than expected quarterly earnings. The stock …

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in pat…

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the …

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fir…

TNGX −8.5% todayRead at source ↗
● Seeking AlphaOct 30, 2026 · 07:08 ET
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity

Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. Company's combination therapy showed an 82% ORR and 88% 9-month…

TNGX −8.5% todayRead at source ↗
● Seeking AlphaOct 28, 2026 · 16:15 ET
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's strong cash position …

TNGX −8.5% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 12:46 ETEARNINGS EXPECTED BY FEB 23
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.…

TNGX −8.5% todayRead at source ↗
● Seeking AlphaOct 23, 2026 · 16:57 ET
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript…

TNGX −8.5% todayRead at source ↗
● MarketBeatOct 23, 2026 · 12:06 ET
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted …

TNGX −8.5% todayRead at source ↗
● BenzingaOct 23, 2026 · 11:36 ET
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.…

TNGX −8.5% todayRead at source ↗
● Investors Business DailyOct 23, 2026 · 06:30 ET
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug

Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.…

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireOct 23, 2026 · 06:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 23
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib…

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireOct 16, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET…

TNGX −8.5% todayRead at source ↗
● Defense WorldOct 6, 2026 · 03:17 ETEARNINGS EXPECTED BY FEB 23
Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis

Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength …

TNGX −8.5% todayRead at source ↗
● Defense WorldSep 23, 2026 · 05:09 ETEARNINGS EXPECTED BY FEB 23
Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey

Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on…

TNGX −8.5% todayRead at source ↗
● Defense WorldSep 18, 2026 · 04:09 ETEARNINGS EXPECTED BY FEB 23
Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

Tidal Investments LLC acquired a new stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 55,384…

TNGX −8.5% todayRead at source ↗
● Zacks Investment ResearchSep 10, 2026 · 12:31 ETEARNINGS EXPECTED BY FEB 23
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?…

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' …

TNGX −8.5% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside ch…

TNGX −8.5% todayRead at source ↗
● Defense WorldAug 27, 2026 · 03:34 ETEARNINGS EXPECTED BY FEB 23
Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX

Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Comm…

TNGX −8.5% todayRead at source ↗
● Defense WorldAug 26, 2026 · 04:13 ETEARNINGS EXPECTED BY FEB 23
Tango Therapeutics, Inc. $TNGX Shares Sold by Bank of America Corp DE

Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The …

TNGX −8.5% todayRead at source ↗
● Defense WorldAug 26, 2026 · 04:13 ETEARNINGS EXPECTED BY FEB 23
ADAR1 Capital Management LLC Invests $2.40 Million in Tango Therapeutics, Inc. $TNGX

ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,761 shares …

TNGX −8.5% todayRead at source ↗

Expected by Feb 23. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just TNGX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.